{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-002562","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2021-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.893911+00:00","generated_at":"2026-06-28T15:49:04.881666+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Compass reports CTX-009 Phase 2a ORR 29% in BTC; proposes public offering and Nasdaq uplist","bullets":["CTX-009 Phase 2a in biliary tract cancer met criteria to advance; 5 partial responses in 17 patients (ORR 29%), 100% clinical benefit rate.","Compass plans to submit US IND this quarter, initiate Phase 2 study in Q2 2022.","Preliminary cash $25.5M as of Sep 30, 2021; proposes underwritten public offering of common stock plus 15% option for underwriters.","Common stock approved for Nasdaq Capital Market listing under symbol CMPX, subject to offering pricing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-002562","json":"https://secwatch.observer/filing/0000950170-21-002562.json","markdown":"https://secwatch.observer/filing/0000950170-21-002562.md","text":"https://secwatch.observer/filing/0000950170-21-002562.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000095017021002562/0000950170-21-002562-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000095017021002562/cmpx-20211101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:49:04.881666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}